The Efficacy and Safety of Hyperthermic Intraperitoneal Chemotherapy （HIPEC）Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis: A Prospective, Single-arm, Phase II Clinical Study
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 69
- 主要终点
- Overall survival
研究概览
简要总结
The prognosis of patients with peritoneal metastasis from gastric cancer is extremely poor. Although chemotherapy combined with immunotherapy has achieved promising efficacy in the first-line treatment of advanced gastric cancer, patients with peritoneal metastasis benefit less from this regimen. Hyperthermic intraperitoneal chemotherapy (HIPEC) represents a novel treatment option, which maintains the high concentration of drugs in the abdominal cavity, and improve the anti-tumor efficacy of chemotherapy drugs through the thermo-thermal effect. The purpose of this study is to investigate the efficacy and safety of HIPEC and systemic chemotherapy combined with sintilimab in the first-line treatment of advanced gastric cancer and gastroesophageal junction adenocarcinoma with peritoneal metastasis.
详细描述
To determine the efficacy and safety of HIPEC and systemic chemotherapy combined with sintilimab in the first-line treatment of advanced gastric cancer with peritoneal metastasis, patients will receive SOX regimen chemotherapy combined with sintilimab, once every three weeks. In the first cycle, HIPEC will be administrated, and HIPEC or intraperitoneal chemotherapy will be administrated in the second to third cycles according to the patient's condition. Then, another 3-cycle SOX regimen of systemic chemotherapy will be administrated. After the end of 6 cycles, patients will receive maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years.
- •Unresectable gastric/gastroesophageal junction adenocarcinoma diagnosed with peritoneal metastasis through laparoscopic exploration and pathological or cytological examination;
- •No previous antitumor treatment.
- •Agree to provide blood/tissue specimens.
- •The expected survival is more than 3 months.
- •Adequate organ function including the following:
- •Total bilirubin ≤1.5 times the upper limit of normal (ULN);
- •Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3×ULN;
- •Alkaline phosphatase≤2.5×ULN (if the tumor invaded the liver, ≤3×ULN);
- •Serum creatinine≤1.5×ULN;
- •Serum amylase and lipase≤1.5×ULN;
- •International standardized ratio (INR)/partial thromboplastin time (PTT)≤1.5×ULN;
- •Platelet count ≥ 75,000 /mm3;
- •Hemoglobin (Hb) ≥ 9 g/dL;
- •Absolute neutrophil count (ANC) ≥ 1500/mm3;
- •Strict contraception.
- •Patients must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
排除标准
- •Undergoing other drug clinical trials or having participated in any drug clinical trials one month before enrollment.
- •Active autoimmune disease or history of refractory autoimmune disease.
- •Receiving corticosteroids (> 10mg/d prednisone or equivalent dose of steroids) or other systematic immunosuppression therapies within 14 days before enrollment, excluding the following therapies: steroid hormone replacement therapy (≤10mg/d); local steroid therapy; and short-term, prophylactic steroid therapy for preventing allergies or nausea and vomiting.
- •Active or clinically significant cardiac disease:
- •Congestive heart failure > New York Heart Association (NYHA) class 2;
- •Active coronary artery disease;
- •Arrhythmias requiring treatment other than β-blockers or digoxin;
- •Unstable angina (with angina symptoms at rest), new angina within 3 months before enrollment, or new myocardial infarction within 6 months before enrollment
- •Gastrointestinal perforation, obstruction, or uncontrollable diarrhea in the 6 months prior to enrollment;
- •Other tumors that have not been treated or exist at the same time, except carcinoma in situ of the cervix, treated basal cell carcinoma or superficial bladder tumor. If the tumor was cured and no evidence of disease was found for more than 3 years, the patient can be enrolled. All other tumors must be treated at least 3 years before enrollment.
- •Patients with pheochromocytoma.
- •Patients with a history of HIV infection or active hepatitis B/C.
- •Ongoing > level 2 infection.
- •Symptomatic brain metastasis or meningioma.
- •Unhealed wounds, ulcers or fractures.
- •Renal failure patients requiring blood or peritoneal dialysis.
- •Epileptic that needs medication.
- •History of organ transplantation (including corneal transplantation).
- •Allergic to research drugs or similar drugs, or suspected allergies.
- •Pregnant or lactating women.
- •Medical, psychological or social conditions can affect the recruitment of patients and evaluation of study results.
- •Other antitumor therapy (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than investigator drugs. Palliative external irradiation for non-target lesions is allowed.
- •Previously used similar chemotherapy drugs or immune checkpoint inhibitors;
- •Major surgery 4 weeks before recruitment, open biopsy or major trauma surgery (excluding biliary stents, or percutaneous biliary drainage).
- •Treatment with antitumor Chinese herbal medicine.
- •Vaccination history 4 weeks prior to enrollment
- •The investigator believes that patients who are not suitable for the study.
研究组 & 干预措施
SOX+sintilimab+HIPEC
Patient will receive SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA < 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated, and HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated in the second and third cycles according to the patient's condition. Then, another 3-cycle SOX regimen of systemic chemotherapy. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
干预措施: S-1, Oxaliplatin sintilimab HIPEC (Drug)
结局指标
主要结局
Overall survival
时间窗: every 3 month postoperation up to 24 months
Overall survival (OS) is defined as the time from randomization to death
次要结局
- DCR(every 3 month postoperation up to 24 months)
- ORR(every 3 month postoperation up to 24 months)
- Progression-free survival(every 3 month postoperation up to 24 months)
- Safety and Tolerability(every 3 month postoperation up to 24 months)
研究者
Bo Zhang, MD
Clinical Professor
Sichuan University